Drugs

PEER-REVIEWED FEATURE

Ublituximab: Adis Evaluation

Key Points

- A glycoengineered monoclonal antibody developed by TG Therapeutics, Inc. for the treatment of multiple sclerosis
- Received its first approval on 28 Dec 2022 in the USA
- Approved for use in adults for the treatment of relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease

Summary

Ublituximab (ublituximab-xiiy; BRIUMVI™) is a glycoengineered anti-CD20 monoclonal antibody developed by TG Therapeutics, Inc. for the treatment of multiple sclerosis (MS).

The mechanism of action of ublituximab involves the depletion of B cells via antibody-dependent cellular cytotoxicity, as B cells have a key role in the pathogenesis of MS. Ublituximab is the first anti-CD20 treatment that is administered twice-yearly as 1-hour infusions, following the initial doses.

In December 2022, ublituximab received its first global approval in the USA for the treatment of adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. This article summarizes the milestones in the development of ublituximab leading to this first approval in this indication.

Lee, A. Drugs. 2023. DOI: 10.1007/s40265-023-01854-z